Simulations Plus announced a newly funded research project with the International Collaboration on Cosmetics Safety or ICCS to evaluate the use of physiologically-based kinetic PBK modeling approaches to advance animal-free science for cosmetics and other non-pharmaceutical ingredients. In a competitive bidding process, Simulations Plus was selected for its proposal to establish workflows for probabilistic PBK modeling of new chemicals based on pharmacokinetic PK analogs. Simulations Plus will review ICCS-provided data, select target-source pairs based on similarity criteria, build PBK models for source chemicals, and apply these in virtual populations to predict exposure for target chemicals. The results and best practices will be published..”We have pioneered the integration of machine learning with PBK models, coupled with limited in vitro data, to accurately predict safety exposure levels in animals and humans,” added Dr. Maxime Le Merdy, Director of PBPK Research & Collaborations at Simulations Plus. “We believe our expertise in this space, combined with ICCS’s commitment to advancing animal-free research and development, will help drive innovation in the non-pharmaceutical markets we serve. As a recognized global leader in modeling and simulation, we look forward to collaborating on this important research project that will help establish best practices and a comprehensive framework as valuable guidance tools for companies and regulatory agencies.” .
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- Craig-Hallum remains bullish on Simulations Plus following quarterly results
- Simulations Plus cuts FY24 EPS view to 54c-56c from 66c-68c
- Simulations Plus Q3 Financials: Expectations and Uncertainties
- Simulations Plus reports Q3 EPS 15c, consensus 15c
- Options Volatility and Implied Earnings Moves Today, July 02, 2024
Questions or Comments about the article? Write to editor@tipranks.com